Literature DB >> 22901538

CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection.

David Bikard1, Asma Hatoum-Aslan, Daniel Mucida, Luciano A Marraffini.   

Abstract

Pathogenic bacterial strains emerge largely due to transfer of virulence and antimicrobial resistance genes between bacteria, a process known as horizontal gene transfer (HGT). Clustered, regularly interspaced, short palindromic repeat (CRISPR) loci of bacteria and archaea encode a sequence-specific defense mechanism against bacteriophages and constitute a programmable barrier to HGT. However, the impact of CRISPRs on the emergence of virulence is unknown. We programmed the human pathogen Streptococcus pneumoniae with CRISPR sequences that target capsule genes, an essential pneumococcal virulence factor, and show that CRISPR interference can prevent transformation of nonencapsulated, avirulent pneumococci into capsulated, virulent strains during infection in mice. Further, at low frequencies bacteria can lose CRISPR function, acquire capsule genes, and mount a successful infection. These results demonstrate that CRISPR interference can prevent the emergence of virulence in vivo and that strong selective pressure for virulence or antibiotic resistance can lead to CRISPR loss in bacterial pathogens.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22901538     DOI: 10.1016/j.chom.2012.06.003

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  135 in total

Review 1.  CRISPR-Cas immunity in prokaryotes.

Authors:  Luciano A Marraffini
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

2.  Bifidobacterium animalis subsp. lactis ATCC 27673 is a genomically unique strain within its conserved subspecies.

Authors:  Joseph R Loquasto; Rodolphe Barrangou; Edward G Dudley; Buffy Stahl; Chun Chen; Robert F Roberts
Journal:  Appl Environ Microbiol       Date:  2013-08-30       Impact factor: 4.792

3.  The Pneumococcal Serotype 15C Capsule Is Partially O-Acetylated and Allows for Limited Evasion of 23-Valent Pneumococcal Polysaccharide Vaccine-Elicited Anti-Serotype 15B Antibodies.

Authors:  Brady L Spencer; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

4.  Bacteriophage Cooperation Suppresses CRISPR-Cas3 and Cas9 Immunity.

Authors:  Adair L Borges; Jenny Y Zhang; MaryClare F Rollins; Beatriz A Osuna; Blake Wiedenheft; Joseph Bondy-Denomy
Journal:  Cell       Date:  2018-07-19       Impact factor: 41.582

Review 5.  Impact of CRISPR immunity on the emergence and virulence of bacterial pathogens.

Authors:  Asma Hatoum-Aslan; Luciano A Marraffini
Journal:  Curr Opin Microbiol       Date:  2013-12-29       Impact factor: 7.934

6.  Francisella novicida CRISPR-Cas Systems Can Functionally Complement Each Other in DNA Defense while Providing Target Flexibility.

Authors:  Hannah K Ratner; David S Weiss
Journal:  J Bacteriol       Date:  2020-05-27       Impact factor: 3.490

7.  Role of the Streptococcus mutans CRISPR-Cas systems in immunity and cell physiology.

Authors:  M A Serbanescu; M Cordova; K Krastel; R Flick; N Beloglazova; A Latos; A F Yakunin; D B Senadheera; D G Cvitkovitch
Journal:  J Bacteriol       Date:  2014-12-08       Impact factor: 3.490

Review 8.  Adapting to new threats: the generation of memory by CRISPR-Cas immune systems.

Authors:  Robert Heler; Luciano A Marraffini; David Bikard
Journal:  Mol Microbiol       Date:  2014-06-04       Impact factor: 3.501

Review 9.  Resistance and tolerance to foreign elements by prokaryotic immune systems - curating the genome.

Authors:  Gregory W Goldberg; Luciano A Marraffini
Journal:  Nat Rev Immunol       Date:  2015-11       Impact factor: 53.106

10.  CRISPR-Cas: to take up DNA or not-that is the question.

Authors:  Ariel D Weinberger; Michael S Gilmore
Journal:  Cell Host Microbe       Date:  2012-08-16       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.